StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research note issued to investors on Saturday. The firm issued a sell rating on the medical technology company’s stock. BIOL has been the topic of several other research reports. Benchmark reaffirmed a speculative buy rating and issued a $2.00 price target on […]
StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a report published on Thursday. The firm issued a sell rating on the medical technology company’s stock. BIOL has been the topic of several other reports. Lake Street Capital reiterated a buy rating on shares of BIOLASE in a research report on Friday, […]
StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research report report published on Wednesday. The brokerage issued a sell rating on the medical technology company’s stock. Separately, Lake Street Capital reissued a buy rating on shares of BIOLASE in a research report on Friday, January 20th. BIOLASE Trading Down 7.0 […]
Benchmark reiterated their speculative buy rating on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research report sent to investors on Wednesday, Benzinga reports. The firm currently has a $2.00 price target on the medical technology company’s stock. Several other equities research analysts have also recently commented on the stock. Lake Street Capital reiterated […]
StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research note issued on Wednesday. The brokerage set a “sell” rating on the medical technology company’s stock. Separately, Lake Street Capital reissued a “buy” rating on shares of BIOLASE in a research report on Friday, January 20th. BIOLASE Stock Performance Shares of […]